Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 22, 2020 | September 26, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date September 22, 2020 · Filed September 26, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,800 |
Reported balance
After 2020-09-22 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-09-22 · Grant · Acquired 9,100 · Balance 35,800 F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2: This restricted stock unit award vests in full, one year following September 22, 2020. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.90 · Expires 2028-09-21 | Direct | 18,200 |
Reported balance
After 2020-09-22 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2020-09-22 · Grant · Acquired 18,200 · Balance 18,200 F3: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
F2: This restricted stock unit award vests in full, one year following September 22, 2020.
F3: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2020 Filed Sep 25, 2020 01:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001209191-20-052044 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052044 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,800 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:14 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001209191-20-052156 · doc4a.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:14 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052156 · doc4a.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,800 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 27, 2019 Filed Oct 2, 2019 23:51 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,000 | $17.84 | $53,520.00 |
DisclosureSEC source: 0001209191-19-051968 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.75 to $17.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 13,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-19-051045 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-09-24 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2019. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051045 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 25, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-19-041725 · doc4.xml · derivative · entry 3 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 10,000 | $34.63 | $346,300.00 |
DisclosureSEC source: 0001209191-19-041725 · doc4.xml · nonDerivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.00 to $35.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 21:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 10,000 | $9.24 | $92,400.00 |
DisclosureSEC source: 0001209191-19-041725 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:24 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 9,500 | $0.00 Strike: $60.91 | $0.00 |
DisclosureSEC source: 0001209191-18-052911 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2026-09-26 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2018. Read SEC document |
| September 27, 2018 Filed Oct 2, 2018 00:24 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052911 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 27, 2018. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,000 | $56.98 | $512,820.00 |
DisclosureSEC source: 0001209191-18-052001 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.32 to $57.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 05, 2018 Filed Apr 10, 2018 00:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001209191-18-024454 · doc4.xml · derivative · entry 3 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 30,000 shares Expires 2020-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2018 Filed Apr 10, 2018 00:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $101.74 | $3,052,200.00 |
DisclosureSEC source: 0001209191-18-024454 · doc4.xml · nonDerivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $100.48 to $103.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| April 05, 2018 Filed Apr 10, 2018 00:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $9.24 | $277,200.00 |
DisclosureSEC source: 0001209191-18-024454 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,000 | $21.97 | $109,850.00 |
DisclosureSEC source: 0001209191-17-053880 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.80 to $22.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-17-053617 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: common stock · 22,500 shares Expires 2025-09-18 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2017. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:49 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053617 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,450 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 19, 2017. Read SEC document |
| July 14, 2017 Filed Jul 19, 2017 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001209191-17-045609 · doc4.xml · derivative · entry 3 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 14, 2017 Filed Jul 19, 2017 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $20.76 | $622,800.00 |
DisclosureSEC source: 0001209191-17-045609 · doc4.xml · nonDerivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $20.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| July 14, 2017 Filed Jul 19, 2017 00:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $14.26 | $427,800.00 |
DisclosureSEC source: 0001209191-17-045609 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 07, 2017 Filed Apr 11, 2017 22:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,000 | $20.05 | $140,350.00 |
DisclosureSEC source: 0001209191-17-026605 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.68 to $20.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001209191-17-014007 · doc4.xml · derivative · entry 3 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $13.08 | $392,400.00 |
DisclosureSEC source: 0001209191-17-014007 · doc4.xml · nonDerivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.99 to $13.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 23:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $5.14 | $154,200.00 |
DisclosureSEC source: 0001209191-17-014007 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001209191-16-142668 · doc4.xml · derivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-09-20 F3 · derivative.exercise_date: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 21:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142668 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,450 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 21, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142027 · doc4.xml · derivative · entry 3 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F2 · derivative.exercise_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F2 · derivative.expiration_date: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142027 · doc4.xml · nonDerivative · entry 2 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents restricted stock units ("RSU"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on September 15, 2015, vested in full one year following the grant date. F3 · balance_after: The total holdings include 15,000 shares of restricted stock units ("RSUs") that were previously reported in Table II for the reporting person and which are being reclassified to Table I. These RSUs were granted on September 15, 2015, are convertible on a one-for-one basis into shares of Common Stock of the Company and vested on September 15, 2016. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 21:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,000 | $19.06 | $171,540.00 |
DisclosureSEC source: 0001209191-16-142027 · doc4.xml · nonDerivative · entry 1 Lingnau Lutz · CIK 0001354179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,450 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.